Subject(s)
Foot Diseases/diagnostic imaging , Hernia/diagnostic imaging , Radio Waves , Skin Diseases, Papulosquamous/diagnostic imaging , Subcutaneous Fat/diagnostic imaging , Adolescent , Female , Foot Diseases/etiology , Foot Injuries/diagnostic imaging , Foot Injuries/etiology , Heel/diagnostic imaging , Heel/injuries , Hernia/etiology , Humans , Martial Arts/injuries , Middle Aged , Obesity/complications , Pressure/adverse effects , Subcutaneous Fat/pathologyABSTRACT
Atopy is almost always associated with an elevated immunoglobulin (Ig) E production. Omalizumab is a monoclonal anti-IgE antibody that is currently indicated for the treatment of cases of asthma that satisfy certain criteria. A number of studies have been published on the usefulness of omalizumab in the treatment of atopic dermatitis, and the results have been variable. We present our experience in the treatment of 9 patients with severe atopic dermatitis refractory to at least 2 systemic drugs. All patients reported a decrease in pruritus and an improvement in quality of life. Good control of the skin disease was achieved with omalizumab in monotherapy in 2 patients, and there was a slight improvement in the eczematous lesions in 4 patients. Those patients who also had asthma achieved good control of their respiratory symptoms and did not require additional therapy. Omalizumab is a well-tolerated and safe drug that can be useful for the treatment of severe atopic dermatitis refractory to other systemic therapies. This monoclonal anti-IgE antibody is a major therapeutic advance as it opens the door to the management of atopic dermatitis using systemic immunomodulating therapies.
Subject(s)
Antibodies, Anti-Idiotypic/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Dermatitis, Atopic/drug therapy , Dermatologic Agents/therapeutic use , Adult , Combined Modality Therapy , Dermatitis, Atopic/immunology , Dermatitis, Atopic/radiotherapy , Drug Evaluation , Female , Humans , Immunoglobulin E/immunology , Immunosuppressive Agents/therapeutic use , Male , Omalizumab , PUVA Therapy , Pruritus/drug therapy , Pruritus/etiology , Quality of Life , Retrospective Studies , Treatment Outcome , Ultraviolet TherapyABSTRACT
La psoriasis es una enfermedad crónica inflamatoria de la piel que afecta a un 2-3% de la población general. Aproximadamente, en uno de cada tres pacientes comienza en la edad infantil, y supone el 4% de todas las enfermedades de la piel del niño. La cara y las zonas de los pliegues se ven afectadas con frecuencia, y además son áreas especialmente sensibles a los efectos adversos de los corticoides tópicos. Los inhibidores de la calcineurina tópicos suponen una opción eficaz y segura en el tratamiento de la psoriasis invertida en niños(AU)
Psoriasis is a chronic inflammatory skin disorder that affects 2% to 3% of the population. Approximately one-third of the patients note its onset during childhood, and it accounts for 4%of the cutaneous disorders in children. The face and intertriginous areas are often involved, and they are particularly sensitive to the adverse effects of steroid use. Topical calcineurin inhibitors are an effective and safe option for the treatment of inverse psoriasis in children(AU)
Subject(s)
Humans , Male , Child, Preschool , Psoriasis/diagnosis , Psoriasis/therapy , Adrenal Cortex Hormones/therapeutic use , Calcineurin/therapeutic use , Tacrolimus/therapeutic use , Diagnosis, Differential , Phototherapy , Skin Diseases, Infectious/diagnosis , Quality of Life , Erythema/complications , Diaper Rash/complications , Diaper Rash/diagnosis , Phototherapy/instrumentation , Phototherapy/methods , Phototherapy/trendsABSTRACT
La dermatitis de Berloque es una fotodermatosis que requiere una anamnesis temporal cuidadosa: el antecedente de la aplicación de la sustancia en la superficie corporal y la exposición solar posterior nos dan la clave para su correcto diagnóstico. Aunque habitual para el dermatólogo, no es un cuadro clínico común en el paciente pediátrico y debe incluirse en el diagnostico diferencial de las dermatitis de contacto, incluso en casos de maltrato infantil(AU)
Berloque dermatitis is a photodermatosis that requires a careful examination of the foregoing sequence of events. The application of a substance to some part of the body prior to sun exposure is the key for an accurate diagnosis. Although it is commonly diagnosed by dermatologists, it is unusual among pediatric patients, and should be included in the differential diagnosis of certain forms of contact dermatitis and even cases of child abuse(AU)